Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation Kanitinib Treatment of Recurrent or Metastatic Malignant Solid Tumors Safety, Tolerability and Pharmacokinetic Open, Dose Escalation Phase I Clinical Study

NCT02916095 is registered in ClinicalTrials.gov with Beijing Konruns Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT02916095
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02916095 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation Kanitinib Treatment of Recurrent or Metastatic Malignant Solid Tumors Safety, Tolerability and Pharmacokinetic Open, Dose Escalation Phase I Clinical Study
Lead sponsor
Beijing Konruns Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2016
Completion date
July 31, 2020
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors